Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: Evidence for premature aging of the myeloid compartment

被引:8
|
作者
Lobetti-Bodoni, Chiara [1 ]
Ferrero, Dario [1 ]
Genuardi, Elisa [1 ]
Passera, Roberto
Bernocco, Elisa [1 ]
Sia, Daniela [2 ]
Grignani, Giovanni [3 ]
Crisa, Elena [1 ]
Monitillo, Luigia [1 ]
Rocci, Alberto [1 ]
Drandi, Daniela [1 ]
Giai, Valentina [1 ]
Zanni, Manuela [1 ]
Boi, Michela [1 ]
Isaia, Gianluca [4 ]
Barbero, Daniela [1 ]
Lunghi, Monia [5 ]
Abruzzese, Elisabetta [6 ]
Radaelli, Franca [7 ]
Pini, Massimo [8 ]
Pregno, Patrizia [9 ]
Carlo-Stella, Carmelo [2 ]
Gaidano, Gianluca [5 ]
Boccadoro, Mario [1 ]
Ladetto, Marco [1 ]
机构
[1] Univ Turin, Div Hematol, AOU San Giovanni Battista, Turin, Italy
[2] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[3] Inst Canc Res & Treatment IRCC, Med Oncol Unit, Candiolo, Italy
[4] Univ Turin, Dept Med & Surg, Geriatr Sect, Turin, Italy
[5] Amedeo Avogadro Univ Eastern Piedmont, Dept Clin & Expt Med, Div Hematol, Novara, Italy
[6] Tor Vergata Univ Hosp, Dept Hematol, Rome, Italy
[7] Fdn IRCCS Policlin, Milan, Italy
[8] AO SS Antonio & Biagio, Div Hematol, Alessandria, Italy
[9] AOU San Giovanni Battista, Div Hematol 2, Turin, Italy
关键词
Telomere shortening; Cytogenetic abnormalities; Bone marrow failure; Tyrosine kinase inhibitors; Hematopoiesis; IMATINIB MESYLATE THERAPY; CLONAL CYTOGENETIC ABNORMALITIES; CHRONIC MYELOGENOUS LEUKEMIA; HIGH-DOSE CHEMOTHERAPY; CHROMOSOMAL-ABNORMALITIES; POLYCLONAL HEMATOPOIESIS; CELLULAR SENESCENCE; CHRONIC-PHASE; DNA-DAMAGE; STEM-CELLS;
D O I
10.1016/j.mad.2012.05.007
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Telomere shortening, a well-known marker of aging and cellular stress, occurs under several conditions in the hematopoietic compartment, including aplastic anemia and following iatrogenic noxae. We decided to verify whether pathological telomere erosion also arises in restored Philadelphia-negative (Ph-negative) hematopoiesis following successful treatment of chronic myeloid leukemia (CML). Eighty-one CML patients in complete cytogenetic remission were compared to 76 age-matched healthy subjects. Myeloid cells of CML patients had shorter telomeres than controls (6521 bp vs 7233 bp, p < 0.001). This difference was specific for the myeloid compartment, since it was not observed in lymphoid cells (6774 bp vs 6909 bp, p = 0.620). Acquired Ph-negative cytogenetic abnormalities (p = 0.010), lack of complete molecular remission (p = 0.016) and age (p = 0.013) were independent predictors of telomere shortening. Telomere dynamics were assessed over a median follow-up period of 22 months. We. documented accelerated non-physiological ongoing telomere shortening in 17/59 CML patients (28%). Patients experiencing grade 2-4 hematological toxicity, during CML remission possessed significantly shorter telomeres compared to those lacking toxicity (p = 0.005 for any toxicity, p = 0.007 for anemia). CML patients suffer from significant and often ongoing telomere stress resulting in premature and selective aging of the myeloid compartment which might have long-term consequences on function and integrity of Ph-negative hematopoiesis. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:479 / 488
页数:10
相关论文
共 50 条
  • [31] Treatment of Philadelphia-Positive Chronic Myeloid Leukemia with Imatinib: Importance of a Stable Molecular Response
    Palandri, Francesca
    Lacobucci, Ilaria
    Soverini, Simona
    Castagnetti, Fausto
    Poerio, Angela
    Testoni, Nicoletta
    Alimena, Giuliana
    Breccia, Massimo
    Rege-Cambrin, Giovanna
    Tiribelli, Mario
    Varaldo, Riccardo
    Abruzzese, Elisabetta
    Martino, Bruno
    Luciano, Luigiana
    Pane, Fabrizio
    Saglio, Giuseppe
    Martinelli, Giovanni
    Baccarani, Michele
    Rosti, Gianantonio
    CLINICAL CANCER RESEARCH, 2009, 15 (03) : 1059 - 1063
  • [32] Telomere length shortening is associated with treatment-free remission in chronic myeloid leukemia patients
    Caocci, Giovanni
    Greco, Marianna
    Delogu, Giuseppe
    Secchi, Christian
    Martino, Bruno
    Labate, Claudia
    Abruzzese, Elisabetta
    Trawinska, Malgorzata Monika
    Galimberti, Sara
    Orru, Federica
    Fozza, Claudio
    Passerini, Carlo Gambacorti
    Galimi, Francesco
    La Nasa, Giorgio
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9
  • [33] Transient trisomy 8 abnormality in Philadelphia-negative cells during imatinib mesylate treatment of chronic myelogenous leukemia
    Kim, M.
    Lee, S.
    Jung, C. K.
    Lim, J.
    Cho, S. G.
    Kim, D. W.
    Kim, Y.
    Han, K.
    Min, W. S.
    Kim, C. C.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2008, 30 (06) : 508 - 512
  • [34] Myelodysplastic Syndrome with Ph Negative Monosomy 7 Chromosome following Transient Bone Marrow Dysplasia during Imatinib Treatment for Chronic Myeloid Leukemia
    Karimata, Kaori
    Masuko, Masayoshi
    Ushiki, Takashi
    Kozakai, Takashi
    Shibasaki, Yasuhiko
    Yano, Toshio
    Abe, Takashi
    Moriyama, Masato
    Toba, Ken
    Furukawa, Tatsuo
    Aizawa, Yoshifusa
    INTERNAL MEDICINE, 2011, 50 (05) : 481 - 485
  • [35] A multicenter real-world evidence study in the Swiss treatment landscape of chronic myeloid leukemia
    Cantoni, Nathan
    Sommavilla, Roberto
    Seitz, Patrick
    Kulenkampff, Elisabeth
    Kahn, Stefan
    Lambert, Jean-Francois
    Schmidt, Adrian
    Zenhaeusern, Reinhard
    Balabanov, Stefan
    BMC CANCER, 2022, 22 (01)
  • [36] Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM)
    Thepot, Sylvain
    Itzykson, Raphael
    Seegers, Valerie
    Raffoux, Emmanuel
    Quesnel, Bruno
    Chait, Yasmine
    Sorin, Lucile
    Dreyfus, Francois
    Cluzeau, Thomas
    Delaunay, Jacques
    Sanhes, Laurence
    Eclache, Virginie
    Dartigeas, Caroline
    Turlure, Pascal
    Harel, Stephanie
    Salanoubat, Celia
    Kiladjian, Jean-Jacques
    Fenaux, Pierre
    Ades, Lionel
    BLOOD, 2010, 116 (19) : 3735 - 3742
  • [37] FDG PET findings of chronic myeloid leukemia in the chronic phase before and after treatment
    Nakajo, Masatoyo
    Jinnouchi, Seishi
    Inoue, Hirosaka
    Otsuka, Maki
    Matsumoto, Tadashi
    Kukita, Toshimasa
    Tanabe, Hiroaki
    Tateno, Rie
    Nakajo, Masayuki
    CLINICAL NUCLEAR MEDICINE, 2007, 32 (10) : 775 - 778
  • [38] Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity
    Schiffer, Charles A.
    Cortes, Jorge E.
    Hochhaus, Andreas
    Saglio, Giuseppe
    le Coutre, Philipp
    Porkka, Kimmo
    Mustjoki, Satu
    Mohamed, Hesham
    Shah, Neil P.
    CANCER, 2016, 122 (09) : 1398 - 1407
  • [39] Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR
    Ross, D. M.
    Branford, S.
    Seymour, J. F.
    Schwarer, A. P.
    Arthur, C.
    Bartley, P. A.
    Slader, C.
    Field, C.
    Dang, P.
    Filshie, R. J.
    Mills, A. K.
    Grigg, A. P.
    Melo, J. V.
    Hughes, T. P.
    LEUKEMIA, 2010, 24 (10) : 1719 - 1724
  • [40] Case Report of acute myeloid leukemia with "WT1, ATRX, CEBPA, CSMD1, IKZF1, and LRP1B mutation and translocation between chromosome 1 and 19" developing from Philadelphia-negative chronic myeloid leukemia after TKI therapy
    Zhu, Huan
    Yang, Bin
    Liu, Jia
    Wu, Wei
    Ling, Yun
    MEDICINE, 2020, 99 (03)